Stem Cells Preparation (Through Plasma Phoresis) at Chughtai Lab

Stem Cells Preparation (Through Plasma Phoresis) at Chughtai Lab

Stem cells are the cornerstone of modern regenerative medicine and cellular therapeutics. In patients undergoing high-dose chemotherapy for hematological malignancies or those requiring bone marrow reconstitution, the collection, preparation, and preservation of peripheral blood stem cells (PBSCs) is a critical clinical milestone. At Chughtai Lab, Stem Cells Preparation (Through Plasma Phoresis) is performed using state-of-the-art automated cell separation technologies. This highly specialized procedure, clinically referred to as leukapheresis or therapeutic cytapheresis, involves extracting whole blood from a patient or a matched healthy donor, separating the mononuclear cell fraction containing the valuable CD34+ hematopoietic stem cells, and returning the remaining blood components (red blood cells, granulocytes, and plasma) back to the individual. The procedure relies on density-gradient centrifugation within a sterile, closed-loop system, ensuring maximum yield, cellular viability, and patient safety. By utilizing advanced flow cytometry and processing protocols, Chughtai Lab provides clinical teams in Lahore and across Pakistan with highly viable, sterile, and quantified stem cell grafts ready for therapeutic transplantation or cryopreservation.

The clinical importance of this procedure cannot be overstated. Hematopoietic stem cells have the unique ability to self-renew and differentiate into all blood cell lineages, including red blood cells, white blood cells, and platelets. Harvesting these cells from the peripheral blood has largely replaced traditional bone marrow harvesting due to its non-invasive nature, faster hematological recovery, and lower procedural risks. Chughtai Lab employs cutting-edge automated apheresis platforms that continuously monitor blood flow, inlet pressure, and interface stability to optimize the collection of mononuclear cells while minimizing platelet depletion and red blood cell contamination. This precise technological approach ensures that the harvested graft contains an optimal therapeutic dose of CD34+ cells, which is the primary determinant of successful engraftment in both autologous and allogeneic transplantation settings.

Clinical Procedure: What to Expect

Patient Preparation

Proper patient preparation is vital to ensure a high yield of stem cells and to maintain patient safety throughout the multi-hour apheresis procedure. Patients and donors must adhere to the following clinical guidelines:

• Stem Cell Mobilization: Because stem cells normally reside in the bone marrow, patients must undergo a mobilization regimen prior to collection. This typically involves daily subcutaneous injections of Granulocyte Colony-Stimulating Factor (G-CSF) for 4 to 5 consecutive days, sometimes combined with chemotherapy or Plerixafor, to stimulate the release of stem cells into the peripheral bloodstream.
• Venous Access Evaluation: A thorough assessment of the patient’s peripheral veins is performed. If the antecubital veins are insufficient to support the high flow rates required for apheresis, a temporary double-lumen central venous catheter (apheresis catheter) must be placed by a clinical specialist prior to the procedure.
• Hydration and Nutrition: Patients are advised to drink 2 to 3 liters of water daily for 48 hours leading up to the procedure to maintain optimal blood volume. A light, low-fat meal should be consumed on the morning of the collection to prevent lipemic plasma, which can interfere with the machine’s optical sensors.
• Calcium-Rich Diet: The anticoagulant used during apheresis (Acid Citrate Dextrose) binds to ionized calcium in the patient’s blood, which can lead to hypocalcemia. Patients are encouraged to consume calcium-rich foods (such as dairy products) or take oral calcium supplements as prescribed in the days preceding the collection.
• Medication Review: Patients must discuss all current medications with their physician. Certain drugs, particularly anticoagulants, antiplatelet agents, or medications affecting blood pressure, may need to be temporarily adjusted or held.

During the Procedure

The stem cell collection process is conducted in a specialized, comfortable clinical environment under the continuous supervision of trained apheresis nurses and clinical hematologists. The step-by-step process includes:

• Patient Positioning: The patient is comfortably positioned in a reclining apheresis chair or bed. Minimal movement of the arms is required if peripheral venous access is utilized.
• Establishing Circulation: The sterile, single-use apheresis kit is loaded into the automated cell separator. The patient is connected to the machine via two intravenous lines (one for drawing blood and one for returning it) or through the double-lumen central catheter.
• Centrifugal Separation: Whole blood is drawn into the machine at a controlled rate. Inside the rapidly spinning centrifuge bowl or channel, the blood is separated into its constituent layers based on density: plasma, platelets, mononuclear cells (including stem cells), and red blood cells.
• Targeted Harvesting: The machine’s optical sensors detect the mononuclear cell layer (the buffy coat) and selectively divert it into a sterile collection bag. The remaining blood components, along with a small amount of citrate anticoagulant, are safely returned to the patient.
• Monitoring and Duration: The procedure typically takes between 3 to 5 hours, during which 2 to 3 times the patient’s total blood volume is processed. Vital signs, blood flow rates, and signs of hypocalcemia (such as tingling around the mouth, muscle cramps, or chills) are continuously monitored. If symptoms of hypocalcemia occur, oral or intravenous calcium is promptly administered.

When is a Stem Cells Preparation Performed?

Autologous Stem Cell Transplantation in Multiple Myeloma

Multiple myeloma is a hematological malignancy characterized by the clonal proliferation of malignant plasma cells in the bone marrow, leading to bone pain, pathological fractures, renal impairment, and anemia. High-dose chemotherapy followed by autologous stem cell transplantation (ASCT) remains the standard of care for eligible patients. Stem cell preparation via apheresis is performed after the patient achieves a clinical response to induction therapy. Harvesting and storing the patient’s own healthy stem cells prior to administering myeloablative chemotherapy allows for the subsequent rescue and rapid reconstitution of the bone marrow, significantly prolonging progression-free survival.

Relapsed or Refractory Hodgkin and Non-Hodgkin Lymphoma

Patients with Hodgkin or non-Hodgkin lymphoma who experience disease relapse or fail to respond to initial front-line chemotherapy regimens often require salvage chemotherapy followed by high-dose consolidation therapy and autologous stem cell rescue. The preparation of stem cells is scheduled once salvage therapy has successfully reduced the tumor burden. By collecting highly viable CD34+ stem cells during the mobilization phase, clinicians can safely administer lethal doses of chemotherapy to eradicate residual lymphoma cells, knowing they can restore the patient’s hematopoietic system using the prepared autologous stem cell graft.

Allogeneic Stem Cell Transplantation for Acute Leukemias

Acute Myeloid Leukemia (AML) and Acute Lymphoblastic Leukemia (ALL) are aggressive bone marrow cancers characterized by the rapid accumulation of dysfunctional, immature white blood cells (blasts). For high-risk or relapsed cases, allogeneic stem cell transplantation from a human leukocyte antigen (HLA)-matched sibling or unrelated donor is required. In this scenario, stem cell preparation is performed on the healthy donor. The harvested stem cells not only reconstitute the recipient’s immune and hematopoietic systems but also provide a therapeutic “graft-versus-leukemia” (GVL) effect, where the donor’s immune cells actively target and destroy any remaining leukemia cells in the patient.

Severe Aplastic Anemia and Bone Marrow Failure Syndromes

Severe aplastic anemia is a life-threatening condition characterized by profound bone marrow hypocellularity, resulting in pancytopenia (severe depletion of red blood cells, white blood cells, and platelets). Patients suffer from extreme fatigue, recurrent severe infections, and life-threatening bleeding episodes. When immunosuppressive therapy is ineffective or in young patients with HLA-matched donors, an allogeneic stem cell transplant is the definitive cure. Stem cell preparation from the matched donor provides the essential hematopoietic progenitor cells needed to repopulate the recipient’s empty bone marrow, restoring normal blood cell production and resolving the clinical symptoms.

Advanced Autoimmune Diseases and Neurological Conditions

In highly selected cases of severe, progressive autoimmune diseases—such as systemic sclerosis, Crohn’s disease, or relapsing-remitting multiple sclerosis—that are refractory to conventional immunosuppressive therapies, autologous hematopoietic stem cell transplantation is utilized as an immune-resetting strategy. The stem cell preparation process collects the patient’s stem cells before they undergo intense immunoablation. The reinfused stem cells then rebuild a new, self-tolerant immune system, halting the autoimmune destruction of tissues and nerves, and offering long-term clinical remission.

What Does a Stem Cells Preparation Detect?

While stem cell preparation is primarily a therapeutic harvesting procedure rather than a diagnostic test, extensive laboratory evaluation of the harvested product is performed to ensure its quality, safety, and therapeutic efficacy. The processing laboratory at Chughtai Lab evaluates the following critical parameters and findings:

• Total CD34+ Absolute Cell Count: Quantifies the total number of hematopoietic stem cells harvested, which determines if the graft is sufficient for transplantation.
• CD34+ Cell Yield per Kilogram: Calculates the stem cell dose relative to the patient’s body weight (minimum target is typically 2.0 x 10^6 CD34+ cells/kg).
• Mononuclear Cell (MNC) Yield: Measures the concentration of lymphocytes and monocytes in the harvested product.
• Total Nucleated Cell (TNC) Count: Evaluates the overall cellularity of the collected graft.
• Cell Viability Percentage: Assesses the percentage of living cells in the product using flow cytometry (7-AAD staining) or dye exclusion.
• CD45+ Leukocyte Concentration: Measures the total white blood cell population in the harvested bag.
• Hematocrit (Hct) of the Product: Evaluates the level of red blood cell contamination, which must be kept low to prevent ABO incompatibility reactions in allogeneic transplants.
• Platelet Concentration: Monitors the degree of platelet carryover in the harvested product to prevent donor/patient thrombocytopenia.
• Granulocyte Contamination: Assesses the presence of mature granulocytes, which can release inflammatory enzymes during storage.
• CD3+ T-Cell Concentration: Critical for allogeneic grafts to estimate the risk of Graft-Versus-Host Disease (GVHD).
• CD56+ Natural Killer (NK) Cell Count: Evaluates the presence of innate immune cells that contribute to the graft-versus-tumor effect.
• CD19+ B-Cell Contamination: Monitors the presence of B lymphocytes in the harvested product.
• Aerobic Bacterial Culture: Ensures the harvested product is free from bacterial contamination during the multi-hour collection.
• Anaerobic Bacterial Culture: Confirms the absence of anaerobic pathogens in the sterile closed system.
• Fungal Culture: Excludes fungal contamination in the cellular product.
• Mycoplasma Testing: Verifies the absence of sub-microscopic mycoplasma species in the cellular graft.
• Endotoxin Levels (LAL Test): Confirms that the product is pyrogen-free and safe for intravenous reinfusion.
• Total Volume of Harvested Product: Measures the fluid volume of the collection bag to calculate cryopreservation requirements.
• Colony-Forming Unit (CFU-GM) Assay: Evaluates the functional proliferative and differentiation capacity of the stem cells in vitro.
• Post-Thaw Cell Viability: Assesses the survival rate of stem cells after being frozen in liquid nitrogen and thawed.
• pH of the Harvested Product: Monitors the physiological stability of the cellular suspension.
• Plasma Free Hemoglobin: Detects if mechanical hemolysis occurred within the apheresis circuit.
• Citrate Concentration: Ensures the residual anticoagulant levels are within safe limits for the patient.
• CD34+ Subpopulation Analysis: Evaluates primitive stem cell subsets (e.g., CD34+CD38-) for long-term engraftment potential.
• Infectious Disease Screening: Confirms the product is negative for HIV, HBV, HCV, CMV, and Syphilis.

Turnaround Time and Report Access at Chughtai Lab

Stem cell preparation is a highly coordinated, time-sensitive procedure. Because clinical decisions regarding whether to perform a second day of apheresis depend on the stem cell yield of the first day, Chughtai Lab prioritizes rapid flow cytometry analysis. The initial CD34+ cell count and viability reports are typically available within a few hours of completing the collection. This rapid turnaround time allows transplant physicians to immediately determine if the target stem cell dose has been achieved. Final sterility cultures and functional assays, which require incubation, are reported over subsequent days. Patients and clinical teams can access these critical reports securely via the Chughtai Lab Mobile App, through the online patient portal on the official Chughtai Lab website, or via direct clinical coordination with the transplant center.

Stem Cells Preparation Findings Overview

Structure / Parameter Evaluated	Normal Findings	Possible Abnormal Findings
CD34+ Cell Yield	≥ 2.0 x 10^6 cells/kg of recipient weight	< 2.0 x 10^6 cells/kg (Suboptimal graft yield)
Cell Viability (Pre-Freeze)	≥ 90% viable cells	< 70% viable cells (Compromised graft quality)
Microbial Sterility	No growth in aerobic, anaerobic, or fungal cultures	Bacterial or fungal growth detected (Contaminated graft)
Hematocrit (RBC Contamination)	< 5%	≥ 5% (Excessive RBC contamination, risk of hemolysis)
Endotoxin Level	< 0.5 EU/mL	≥ 0.5 EU/mL (Pyrogenic contamination)
Total Nucleated Cells (TNC)	≥ 1.0 x 10^8 cells/kg	< 1.0 x 10^8 cells/kg (Poor collection efficiency)
CD3+ T-Cell Dose (Allogeneic)	Within target therapeutic range (1-3 x 10^8 cells/kg)	Excessively high (Increased GVHD risk) or low (Graft failure)

Note: Diagnostic findings should always be interpreted by a qualified healthcare professional together with the patient’s symptoms, medical history, physical examination, laboratory investigations, previous imaging studies, and other relevant clinical information. Additional investigations or specialist consultation may be recommended depending on the findings.

Why Choose Chughtai Lab for Stem Cells Preparation?

• Experienced Healthcare Professionals: The procedure is supervised by highly qualified consultant hematologists and clinical pathologists specializing in cellular therapies.
• Patient-Focused Care: Dedicated apheresis suites designed to provide maximum patient comfort, safety, and continuous clinical monitoring during long procedures.
• Quality Diagnostic Services: Chughtai Lab operates under strict quality control protocols, adhering to international laboratory standards.
• Professional Reporting: Rapid and precise CD34+ quantification using advanced flow cytometry platforms to guide immediate clinical decisions.
• Modern Diagnostic Approach: Utilization of state-of-the-art automated apheresis systems that optimize stem cell collection while ensuring patient safety.
• Comfortable Environment: A clean, sterile, and welcoming clinical setting designed to reduce patient anxiety and facilitate a smooth collection process.
• Convenient Location: Centrally located specialized collection facilities in Lahore and major cities, ensuring easy accessibility for patients across Pakistan.
• Commitment to Accurate Diagnosis: Seamless integration of laboratory processing, cryopreservation, and clinical reporting to support successful transplant outcomes.